CA125、SCC、SOX2-Ab联合检测对早期肺癌诊断的临床价值研究

Clinical value of combined detection of CA125,SCC and SOX2-Ab in the diagnosis of early lung cancer

目的探讨血清糖类抗原125(carbohydrate antigen 125,CA125)、鳞状上皮细胞癌抗原(squamous cell carcinoma antigen,SCC)及干细胞核心转录因子性别决定区Y框蛋白2自身抗体(Sox2 autoantibodies,SOX2-Ab)联合检测对早期肺癌诊断的临床价值。方法选择2020年7月至2021年6月在聊城市第二人民医院进行健康查体者、肺部良性结节者、肺癌患者各50例,分别为查体组、良性结节组和肺癌组。应用化学发光分析仪及其相应配套试剂测定三组受试者血清CA125、SCC水平,选用适用的酶联免疫吸附试验测定三组受试者SOX2-Ab蛋白含量,并计算受试者操作特征曲线。结果肺癌组患者血清CA125、SCC、SOX2-Ab的水平分别为38.50(22.75,51.25)U/ml、3.08(1.40,3.60)ng/ml、13.45(10.80,15.43)ng/ml,均高于查体组、良性结节组;CA125、SCC、SOX2-Ab联合检测对早期肺癌的检测敏感度、特异性、准确性分别为91%、61%、86%,除特异性外均优于CA125、SCC、SOX2-Ab单独检测。结论CA125、SCC、SOX2-Ab联合检测对早期肺癌诊断敏感度较高,可作为早期肺癌筛查的检测方案。

Objective To investigate the clinical value of combined detection of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC)and Sox2 autoantibodies(SOX2-Ab)in the diagnosis of early lung cancer.Methods 50 healthy persons,50 patients with benign pulmonary nodules and 50 patients with lung cancer were selected from July 2020 to June 2021,as physical examination group,benign pulmonary nodules group and lung cancer group respectively.The serum levels of CA125 and SCC were measured by chemiluminescence analyzer and its related reagents,and the protein content of SOX2-Ab was determined by enzyme linked immunosorbent assay.The receiver operating characteristic curve was calculated.Results The expression levels of CA125,SCC and SOX2-Ab in lung cancer group were 38.50(22.75,51.25)U/ml,3.08(1.40,3.60)ng/ml,13.45(10.80,15.43)ng/ml,respectively.The sensitivity,specificity and accuracy of combined detection of CA125,SCC and SOX2-Ab for early lung cancer were 91%,61%and 86%,respectively.Conclusion The combined detection of CA125,SCC and SOX2-Ab protein is sensitive to the diagnosis of early lung cancer,and can be used as a detection scheme for early lung cancer.